The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Oct. 21, 2025

Filed:

Jun. 08, 2022
Applicants:

Ose Immunotherapeutics, Nantes, FR;

Nantes Universite, Nantes, FR;

Institut National DE LA Sante ET DE LA Recherche Medicale, Paris, FR;

Inventors:

Sabrina Pengam, St Luce S/ Loire, FR;

Vanessa Gauttier, Reze, FR;

Caroline Mary, Sainte-Pazanne, FR;

Nicolas Poirier, Grandchamps des Fontaines, FR;

Marion Drouin, Savenay, FR;

Elise Chiffoleau, Nantes, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); A61K 39/395 (2006.01); A61P 35/00 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2851 (2013.01); A61K 39/3955 (2013.01); A61K 39/39558 (2013.01); A61P 35/00 (2018.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); C07K 2317/24 (2013.01); C07K 2317/73 (2013.01); C07K 2317/76 (2013.01);
Abstract

The invention pertains to the field of immunotherapy. The present invention provides specific humanized anti-CLEC-1A antibodies, antigen-binding fragments thereof and mimetics thereof, in particular antibodies. The compounds of the invention are able to specifically binds to CLEC-1A receptor and antagonize the binding of CLEC-1A to its endogenous ligand(s). The compounds of the invention can be used to treat deleterious conditions.


Find Patent Forward Citations

Loading…